Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up

被引：106

作者：

Popat, Rakesh ^{[1
]}

Oakervee, Heather E. ^{[1
]}

Hallam, Simon ^{[1
]}

Curry, Nicola ^{[1
]}

Odeh, Liz ^{[1
]}

Foot, Nicola ^{[1
]}

Esseltine, Dixie-Lee ^{[2
]}

Drake, Mary ^{[3
]}

Morris, Curly ^{[3
]}

Cavenagh, Jamie D. ^{[1
]}

机构：

[1] St Bartholomews Hosp, Dept Haematol, London EC1A 7BE, England

[2] Millennium Pharmaceut Inc, Cambridge, MA USA

[3] Belfast City Hosp, Belfast BT9 7AD, Antrim, North Ireland

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2008年 / 141卷 / 04期

关键词：

multiple myeloma; bortezomib; doxorubicin; dexamethasone; induction;

D O I：

10.1111/j.1365-2141.2008.06997.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bortezomib, doxorubicin and dexamethasone (PAD) was evaluated as induction before stem cell transplantation in newly diagnosed multiple myeloma (MM) patients, using bortezomib 1.3 mg/m(2) (PAD1, N = 21) or 1.0 mg/m(2) (PAD2, N = 20). Complete/very good partial response rates with PAD1/PAD2 were 62%/42% postinduction and 81%/53% post-transplant. Progression-free survival (29 vs. 24 months), time to re-treatment (36 vs. 29 months) and overall survival (1 year: 100% vs. 95%; 2 years: 95% vs. 73%) were statistically similar but favoured PAD1 versus PAD2. Toxicity was lower in PAD2; bortezomib dose reduction may help manage toxicities while retaining efficacy. PAD is highly active as front-line induction in MM.

引用

页码：512 / 516

页数：5

共 13 条

[11] PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma [J].

Oakervee, HE ;

Popat, R ;

Curry, N ;

Smith, P ;

Morris, C ;

Drake, M ;

Agrawal, S ;

Stec, J ;

Schenkein, D ;

Esseltine, DL ;

Cavenagh, JD .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (06) :755-762

[12]

Perelman M.I., 2007, NATL CLIN GUIDELINES

[13] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma [J].

Richardson, PG ;

Sonneveld, P ;

Schuster, MW ;

Irwin, D ;

Stadtmauer, EA ;

Facon, T ;

Harousseau, JL ;

Ben-Yehuda, D ;

Lonial, S ;

Goldschmidt, H ;

Reece, D ;

San-Miguel, JF ;

Bladé, J ;

Boccadoro, M ;

Cavenagh, J ;

Dalton, WS ;

Boral, AL ;

Esseltine, DL ;

Porter, JB ;

Schenkein, D ;

Anderson, KC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (24) :2487-2498

← 1 2 →